Form 4 for LH Labcorp
Accepted 2022-03-29 00:00:00 ET · period of report 2022-03-27 · accession 0001127602-22-010503 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-29 | 2022-03-28 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $276.42 | -1,648 | 11.9K | -12% | -$455.5K | |
| 2022-03-29 | 2022-03-27 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | A - Grant | $0.00 | +3,707 | 13.6K | +38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-28 | F | D | 1,648 | $276.42 | 11,915 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-27 | A | A | 3,707 | $0.00 | 13,563 | D | — | — |